# Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

> **NCT00099268** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 747 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Carbidopa/levodopa/entacapone
- **DRUG:** Immediate release carbidopa/levodopa

## Key facts

- **NCT ID:** NCT00099268
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 747 (ACTUAL)
- **Last updated:** 2012-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00099268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00099268, "Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00099268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*